|[February 15, 2013]
Stanford Researchers Present Data on Highly Accurate Diagnostic Test for Preeclampsia in Development by Carmenta Bioscience
PALO ALTO, Calif. --(Business Wire)--
Carmenta (News - Alert) Bioscience, Inc., in collaboration with researchers at Stanford
University, today announced presentation of results from a retrospective
clinical study at the 2013 Society of Maternal Fetal Medicine national
meeting. The presentation revealed a new confirmatory diagnostic test
highly accurate in distinguishing mothers with preeclampsia from a
control group in the study.
The underlying technology for the test was discovered by Carmenta's
co-founders, Dr. Atul Butte and Dr. Bruce Ling of Stanford University.
Dr. Butte and Dr. Ling analyzed genomic and proteomic data from over 100
preeclamptic mothers to develop a novel, proprietary panel of serum
proteins capable of diagnosis. Using advanced data mining techniques,
they identified a multiplexed panel of biomarkers representing the broad
diversity of biological processes associated with the condition.
"Given the complicated pathophysiology of preeclampsia, it is necessary
to use a systems biology approach to understand and characterize the
condition. The complex etiology can manifest itself diffrently in
mothers, so a personalized medicine approach is optimal when diagnosing
preeclampsia," said Dr. Butte, Chief, Division of Systems Medicine,
Department of Pediatrics at Stanford University School of Medicine.
The multisite study examined the test in the serum of 64 pregnant
mothers of various ages, gestational ages, and ethnicities, including 32
diagnosed with preeclampsia. The test performed at a high degree of
sensitivity and specificity. The results of the study have been
submitted for publication in a peer-reviewed medical journal.
"We are excited by the results from the initial study, so we are
preparing for an additional, prospective clinical validity trial in
2013. Once the performance of the test is qualified in a larger
population, we will be poised to make the test available to the Maternal
Fetal Medicine and OB-GYN community," said Dr. Matthew Cooper (News - Alert),
Carmenta's President and Chief Executive Officer. Carmenta has obtained
an option to acquire a world-wide, exclusive license from Stanford on
the discovery and is currently developing the test for commercialization.
Preeclampsia is a disorder associated with pregnancy and the postpartum
period affecting both the mother and the unborn baby. Estimated to
affect 5-8% of all pregnancies, preeclampsia is a leading cause of
preterm birth and maternal/fetal death. The condition manifests itself
clinically with high blood pressure and the presence of protein in the
urine after 20 weeks gestation.
About Carmenta Bioscience
Carmenta Bioscience is a privately held, medical technology company
focused on advancing maternal and fetal health by applying a systems
biology approach to the diagnosis and prediction of preeclampsia. For
more information regarding Carmenta Bioscience, please visit www.carmentabio.com.
[ Back To Smart Grid Home's Homepage ]